Literature DB >> 22977358

What We Know about the Molecular Genetics of Central Nervous System (CNS) Tumours in Malaysia.

Sarina Sulong1, Abdul Aziz Mohamed Yusoff, Norafiza Zainuddin, Jafri Malin Abdullah, Jain George Pannatil, Hasnan Jaafar, Mohd Nizam Isa.   

Abstract

The new millennium has been regarded as a genomic era. A lot of researchers and pathologists are beginning to understand the scientific basis of molecular genetics and relates with the progression of the diseases. Central nervous system (CNS) tumours are among the most rapidly fatal of all cancers. It has been proposed that the progression of malignant tumours may result from multi-step of genetic alterations, including activation of oncogenes, inactivation of tumour suppressor genes and also the presence of certain molecular marker such as telomerase activity. In this paper, we review some recent data from the literature, including our own studies, on the molecular genetics analysis in CNS tumours. Our studies have shown that two types of tumour suppressor genes, p53 and PTEN were involved in the development of these tumours but not in p16 gene among the patients from Hospital Universiti Sains Malaysia (HUSM). Telomerase activity also has been detected in various types of CNS tumours. Thus, it is important to assemble all data which related to this study and may provide as a vital information in a new approach to neuro-oncology studies in Malaysia.

Entities:  

Keywords:  CNS tumours; Malaysia; molecular genetics

Year:  2004        PMID: 22977358      PMCID: PMC3438149     

Source DB:  PubMed          Journal:  Malays J Med Sci        ISSN: 1394-195X


  74 in total

1.  T antigen is bound to a host protein in SV40-transformed cells.

Authors:  D P Lane; L V Crawford
Journal:  Nature       Date:  1979-03-15       Impact factor: 49.962

2.  Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction.

Authors:  M Orita; Y Suzuki; T Sekiya; K Hayashi
Journal:  Genomics       Date:  1989-11       Impact factor: 5.736

Review 3.  The p53 tumour suppressor gene.

Authors:  A J Levine; J Momand; C A Finlay
Journal:  Nature       Date:  1991-06-06       Impact factor: 49.962

4.  Expression of the p53 protein in a spectrum of astrocytic tumours.

Authors:  D W Ellison; K C Gatter; P V Steart; D P Lane; R O Weller
Journal:  J Pathol       Date:  1992-12       Impact factor: 7.996

Review 5.  The molecular genetics of central nervous system tumors.

Authors:  H K Ng; P Y Lam
Journal:  Pathology       Date:  1998-05       Impact factor: 5.306

6.  Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma.

Authors:  T Mori; K Miura; T Aoki; T Nishihira; S Mori; Y Nakamura
Journal:  Cancer Res       Date:  1994-07-01       Impact factor: 12.701

7.  WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis.

Authors:  W S el-Deiry; J W Harper; P M O'Connor; V E Velculescu; C E Canman; J Jackman; J A Pietenpol; M Burrell; D E Hill; Y Wang
Journal:  Cancer Res       Date:  1994-03-01       Impact factor: 12.701

8.  Somatic mutations of the MTS (multiple tumor suppressor) 1/CDK4l (cyclin-dependent kinase-4 inhibitor) gene in human primary non-small cell lung carcinomas.

Authors:  N Hayashi; Y Sugimoto; E Tsuchiya; M Ogawa; Y Nakamura
Journal:  Biochem Biophys Res Commun       Date:  1994-08-15       Impact factor: 3.575

Review 9.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.

Authors:  M S Greenblatt; W P Bennett; M Hollstein; C C Harris
Journal:  Cancer Res       Date:  1994-09-15       Impact factor: 12.701

10.  Loss of heterozygosity on chromosome 10, 13q(Rb), 17p, and p53 gene mutations in human brain gliomas.

Authors:  S H Lee; J H Kim; C H Rhee; Y S Kang; J H Lee; S I Hong; K S Choi
Journal:  J Korean Med Sci       Date:  1995-12       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.